OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel in vitro diagnostic test designed to detect bacterial nucleic acids; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. It also provides Acuitas MDRO Gene Test, Acuitas CR Elite Test, and Acuitas Resistome Test that are CLIA lab-based tests, which provide a profile of MDRO resistant genes for surveillance and response to outbreaks. In addition, the company offers Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information, and provide analytics to enable manage MDROs in the hospital and patient care environment. Further, it engages in the development of Acuitas Rapid Test designed to detect urinary tract infection. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone240-813-1260
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.95 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableNot Optionable
OpGen (NASDAQ:OPGN) Frequently Asked Questions
What is OpGen's stock symbol?
OpGen trades on the NASDAQ under the ticker symbol "OPGN."
When did OpGen's stock split? How did OpGen's stock split work?
Shares of OpGen reverse split on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.
How were OpGen's earnings last quarter?
OpGen Inc (NASDAQ:OPGN) issued its quarterly earnings results on Tuesday, February, 26th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.09. OpGen had a negative return on equity of 232.38% and a negative net margin of 453.73%. View OpGen's Earnings History.
When is OpGen's next earnings date?
What price target have analysts set for OPGN?
2 equities research analysts have issued 12-month target prices for OpGen's stock. Their forecasts range from $2.30 to $6.00. On average, they anticipate OpGen's share price to reach $4.15 in the next twelve months. This suggests a possible upside of 243.0% from the stock's current price. View Analyst Price Targets for OpGen.
What is the consensus analysts' recommendation for OpGen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.
Has OpGen been receiving favorable news coverage?
News coverage about OPGN stock has trended somewhat positive on Tuesday, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OpGen earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are some of OpGen's key competitors?
Some companies that are related to OpGen include Leap Therapeutics (LPTX), TRACON Pharmaceuticals (TCON), Avacta Group (AVCT), Mannatech (MTEX), Obalon Therapeutics (OBLN), Zelda Therapeutics (ZLD), Helix Biopharma (HBPCF), AIT Therapeutics (AITB), DiaMedica Therapeutics (DMAC), Oncomed Pharmaceuticals (OMED), TSO3 (TOS), Amryt Pharma (AMYT), ImmuCell (ICCC), Novoheart (NVH) and Fuse Medical (FZMD).
What other stocks do shareholders of OpGen own?
Who are OpGen's key executives?
OpGen's management team includes the folowing people:
- Mr. Evan Jones, Chairman & CEO (Age 62)
- Mr. Timothy C. Dec, CFO, Principal Accounting Officer & Corp. Sec. (Age 60)
- Mr. Vadim Sapiro, Chief Information Officer (Age 48)
- Mr. Michael Farmer, VP of Marketing
- Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60)
When did OpGen IPO?
(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.
Who are OpGen's major shareholders?
OpGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.24%). Company insiders that own OpGen stock include Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.
Which major investors are buying OpGen stock?
OPGN stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp. Company insiders that have bought OpGen stock in the last two years include Jven Capital, Llc and Timothy C Dec. View Insider Buying and Selling for OpGen.
How do I buy shares of OpGen?
Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OpGen's stock price today?
One share of OPGN stock can currently be purchased for approximately $1.21.
How big of a company is OpGen?
OpGen has a market capitalization of $10.46 million and generates $2.95 million in revenue each year. The medical research company earns $-13,370,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.
What is OpGen's official website?
How can I contact OpGen?
OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]
MarketBeat Community Rating for OpGen (NASDAQ OPGN)
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
